TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma

Dreyling, 2014, Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 25, iii83, 10.1093/annonc/mdu264 Zucca, 1995, Patterns of survival in mantle cell lymphoma, Ann Oncol, 6, 257, 10.1093/oxfordjournals.annonc.a059155 Dreyling, 2005, Blood, 105, 2677, 10.1182/blood-2004-10-3883 Herrmann, 2009, Improvement of overall survival in advanced stage mantle cell lymphoma, J Clin Oncol, 27, 511, 10.1200/JCO.2008.16.8435 Hoster, 2008, A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma, Blood, 111, 558, 10.1182/blood-2007-06-095331 Banks, 1992, Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data, Am J Surg Pathol, 16, 637, 10.1097/00000478-199207000-00001 Gazzo, 2005, Atypical cytogenetic presentation of t(11;14) in mantle cell lymphoma, Haematologica, 90, 1708 Cohen, 2015, Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma, Clin Lymphoma Myeloma Leuk, 15, 278, 10.1016/j.clml.2014.12.012 Greenwell, 2018, Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy, Cancer, 124, 2306, 10.1002/cncr.31328 Sarkozy, 2014, Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index, Genes Chromosomes Cancer, 53, 106, 10.1002/gcc.22123 Dong, 2012, TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage, Med Oncol, 29, 2166, 10.1007/s12032-011-0096-5 Puiggros, 2017, Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions, Oncotarget, 8, 54297, 10.18632/oncotarget.17350 Zenz, 2010, TP53 mutation and survival in chronic lymphocytic leukemia, J Clin Oncol, 28, 4473, 10.1200/JCO.2009.27.8762 Rossi, 2009, The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness, Clin Cancer Res, 15, 995, 10.1158/1078-0432.CCR-08-1630 Aukema, 2018, Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network, Blood, 131, 417, 10.1182/blood-2017-07-797019 Eskelund, 2017, TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy, Blood, 130, 1903, 10.1182/blood-2017-04-779736 Swerdlow, 2016, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, 127, 2375, 10.1182/blood-2016-01-643569 McGowan-Jordan J, Simons A, Schmid M. ISCN 2016: an international system for human cytogenomic nomenclature (2016). Reprint of: Cytogenetic and Genome Research 2016, Vol. 149, No. 1-2. Kruzova, 2017, Gender, age and TP53 aberrations in context of complex karyotypes in chronic lymphocytic leukemia patients in the era of chemo +/- immunotherapy, Blood, 130, 2991 Hoster, 2016, Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network, J Clin Oncol, 34, 1386, 10.1200/JCO.2015.63.8387 Ye, 2017, Smoldering mantle cell lymphoma, J Exp Clin Cancer Res, 36, 185, 10.1186/s13046-017-0652-8